Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merrimack Pharmaceuticals
Woman and Man Max 99 years
Merrimack Pharmaceuticals, Inc
Update Il y a 4 ans
A Study of MM-111 and Paclitaxel with or without Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and Stomach Estudio de MM-111 y paclitaxel con o sin trastuzumab en pacientes con carcinoma con cáncer de esófago, unión gastroesofágica o estómago con metastástasis o localmente avanzado
The primary objective of the study is to compare the Progression Free Survival (PFS) between the experimental and comparator arms within two distinct patient populations: Patients with ?Traditional? ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merrimack Pharmaceuticals, Inc
Update Il y a 4 ans
A phase 2 study comparing MM-302 plus trastuzumab versus Chemotherapy of Physicians Choice plus trastuzumab in HER2+ metastatic breast cancer patients
To determine whether the combination of MM-302 plus trastuzumab is more effective than chemotherapy of physician’s choice (CPC) plus trastuzumab based on progression free survival (PFS) as assessed by...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merrimack Pharmaceuticals
Update Il y a 4 ans
Étude SHERLOC MM-121-01-02-09 : étude de phase 2, randomisée, comparant l’efficacité d’un traitement associant le MM-121, un anticorps anti-HER3, au docétaxel ou au pémétrexed à un traitement par docétaxel ou pémétrexed seul, chez des patients ayant un cancer du poumon non à petits cellules localement avancé ou métastatique et présentant un test positif pour l’héréguline.
Le cancer du poumon non à petites cellules est le type de cancer du poumon le plus fréquent, qui représente 85-90% de l’ensemble des cancers du poumon. Environ la moitié des patients de cancer du poum...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merrimack Pharmaceuticals, Inc
Update Il y a 4 ans
A study of MM-398 with or without 5-Fluorouracil and Leucovorin compared with 5- Fluorouracil and Leucovorin in Patients with advanced pancreatic cancer who were previously treated unsuccessfully with a gemcitabine-based therapy
To compare overall survival following treatment with MM-398, with orwithout 5-fluorouracil and leucovorin,versus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer that have ...
Country
None
organs
None
Specialty
None
Closed trial
More information